NCT00596804 2021-08-18Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaGilead SciencesPhase 1/2 Completed39 enrolled
NCT01101581 2021-08-18Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLGilead SciencesPhase 1/2 Withdrawn